Evidence map›Paper›PMID 23058478›Full record

ReviewAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2013

Uric acid as a target of therapy in CKD.

Diana I Jalal, Michel Chonchol, Wei Chen, Giovanni Targher

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 9 pooled it
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

127 citing papers in PubMed, 9 syntheses or guidelines pooled it, 272 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2020
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Vascular Function and Uric Acid-Lowering in Stage 3 CKD.Journal of the American Society of Nephrology : JASN · 2017
    Trial
  19. The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2014
    Trial
  20. Article

67 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 3 countries.

Diana I JalalDivision of Renal Diseases and Hypertension, University of Colorado School of Medicine, Denver, CO 80045, USA. diana.jalal@ucdenver.edu
Michel Chonchol
Wei Chen
Giovanni Targher
University of Colorado Denver · USAzienda Ospedaliera Universitaria Integrata Verona · IT

Funding

Adipokines in Hemodialysis PatientsR01DK078112 · NIDDK · UNIVERSITY OF UTAH · PI BEDDHU, SRINIVASAN · 2008 to 2011
$2.2M
Vitamin D and Clinical Outcomes in Chronic Hemodialysis PatientsR01DK081473 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI CHONCHOL, MICHEL BENJAMIN · 2009 to 2012
$1.4M
Uric Acid as a Mediator of Endothelial Dysfunction in Patients with CKDK23DK088833 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI JALAL, DIANA I · 2010 to 2014
$897k
NIDDK NIH HHS 1K23DK088833NIDDK NIH HHS 1R01DK078112-01A2NIDDK NIH HHS 1R01 DK081473-01A1NIDDK NIH HHS K23 DK088833NIDDK NIH HHS R01 DK078112NIDDK NIH HHS R01 DK081473
6 · The paper itself

Abstract

The prevalence of chronic kidney disease (CKD) has increased and will continue to increase in the United States and worldwide. This is alarming considering that CKD is an irreversible condition and patients who progress to chronic kidney failure have reduced quality of life and high mortality rates. As such, it is imperative to identify modifiable risk factors to develop strategies to slow CKD progression. One such factor is hyperuricemia. Recent observational studies have associated hyperuricemia with kidney disease. In addition, hyperuricemia is largely prevalent in patients with CKD. Data from experimental studies have shown several potential mechanisms by which hyperuricemia may contribute to the development and progression of CKD. In this article, we offer a critical review of the experimental evidence linking hyperuricemia to CKD, highlight gaps in our knowledge on the topic as it stands today, and review the observational and interventional studies that have examined the potential nephroprotective effect of decreasing uric acid levels in patients with CKD. Although uric acid also may be linked to cardiovascular disease and mortality in patients with CKD, this review focuses only on uric acid as a potential therapeutic target to prevent kidney disease onset and progression.

Indexed as

Disease ProgressionHumansHyperuricemiaPredictive Value of TestsRenal Insufficiency, ChronicUric AcidXanthine OxidaseUric AcidXanthine Oxidase

Identifiers

PMID23058478
PMCPMC3525781
OpenAlexW2061170857

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.